MedTrace Logo

A RWS of the FARAPULSE in A Chinese Population With PAF

NCT05493852 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2025-01-31

Study results available
· View outcomes & findings →

Summary

The real world study is a retrospective and/or prospective, single-center, single-arm observational study to observe the safety and effectiveness of the FARAPULSE Pulsed Field Ablation System for treatment of recurrent, symptomatic Paroxysmal Atrial Fibrillation (PAF) in a Chinese population.

Conditions

  • Paroxysmal Atrial Fibrillation

Interventions

DEVICE

FARAPULSE Pulsed Field Ablation System

Patients diagnosed as paroxysmal atrial fibrillation with indication of ablation will be treated by FARAPULSE Pulsed Field Ablation System.

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Minglong Chen, Dr · Boao Super Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-24
Primary Completion
2023-08-21
Completion
2024-07-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05493852 on ClinicalTrials.gov